# Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania

> **NCT00513669** · PHASE1 · COMPLETED · sponsor: **Swiss Tropical & Public Health Institute** · enrollment: 50 (actual)

## Conditions studied

- Falciparum Malaria

## Interventions

- **BIOLOGICAL:** PEV 301& 302 in virosomes
- **BIOLOGICAL:** Inflexal V (active comparator)

## Key facts

- **NCT ID:** NCT00513669
- **Lead sponsor:** Swiss Tropical & Public Health Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513669, "Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00513669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*